Study of ALXN2050 in Participants With Hepatic Impairment

NCT05259085 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision.

Conditions

Impaired Hepatic Function
Healthy

Interventions

DRUG: ALXN2050

Sponsor

Alexion Pharmaceuticals, Inc.